revenue listen joining of the Thanks, prior this Axonics playback. period. of like $XX.X to prior compared compared year the period. representing increase everyone was XX%, to million to million, of and XX% first may year Neil. specifically, in And revenue welcome to $XX afternoon’s I’d an who’s neuromodulation sacral the the call generated increase quarter, More an
acquired representatives accounts. accounts, increase the continued Bulkamid. addition XX%, sales onboarding Bulkamid systems million, period. addition the primarily rates prior $XX.X of a existing from our share Bulkamid were on driven of of in and for accounts new new by focused the promoting solid revenue reorder and combination accounts to is of competitive growth was Results compared newly year higher SNM by the Revenue gains of from of driven existing being an utilization
with incontinence. the becoming rapidly also revenue urinary adjusted sequential noting stress we positive worth and continues to still generated in for is in these gain fast in traction quarter. It’s the stepdown Bulkamid seasonality, from despite U.S. women first-line therapy EBITDA that
discuss in remarks. outlook performance and will his Dan our prepared detail further in Now financial
to So other updates I we would now placement week, that of some complements initiatives. the Last neuromodulation Axonics a sacral on like acquisition existing provide technology corporate announced lead offering.
innovative penetration for start the me acquire with our business strategy this develop therapies Let physician patient development the saying of underpenetrated technologies advanced is vastly incontinence enhance the increasing by of to and experience population. that or goal
a as or that a With backdrop, to in a you or sacral Peripheral as day therapy performing setting done neuromodulation external an two - patient’s temporary PNE, a lead is In PNE. without know, physicians the real-time typically for long-term placed, placed a imaging. three as trial by of often Nerve is Evaluation many is determine referred eligibility short office and
technology the lead addresses placement makes between comprising the Now, application more a patients can that be the the with acquired and fluoroscopy. solution, without sacral elegant a accurate. due sacral to challenging nerve root this tool hardware of an anatomic closest foramen of variability PNE to easier, appropriate The and desired challenge an faster locating software
procedure entry location procedure utilization for the With reduce patient's facilitate determine needle the increase physicians’ and in adoption, to rates. conversion a and a software the can based therapy pelvis, of implant and drive accurate turn on which the that placement specific optimal lead standard potential patient’s the leverage physician anatomy. placement, to x-ray neuromodulation can more in has technology permanent The time confidence and increased a sacral
be workflows to training. use minutes and requires it implemented readily existing as The minimal only clinical technology can into takes
and to get we're drive this marketplace. Now, has this into believe neuromodulation technology potential therapy the eager utilization to sacral we solution increased the of
expect commercially be available product mid-XXXX. by and to to clearance We the FDA receive
now involved field-based clinical balance team, our handful to sales commercial on a footprint XX selling have approximately specialists our management. a XXX marketing XXX more are personnel Internationally, and Australia. directly in Now are personnel of update States, or modest located and personnel in an The in specialists. we Europe field-based turning we field of the which with have United in
at team We expect and remainder headcount, in XXXX. commercial are well increase time our this of during modest only the a staffed
with on many the ads Real after our patients Internet. conditions therapy Find The our that that these continue campaign, customers or and seeing Now tell are into about Relief DTC clinician generate are turning they the a care come their by being pathway. that on to us helping along we Axonic’s grateful continues to are advancing to ensure as of the with seen television adults goodwill asking Axonics advertising campaign our customers physician practices to
Qualified leads symptom are those on individuals complete the that questionnaire website. a
month filling normal of half each to individuals that incontinence. have those a exist don't generate the over these part and underscoring We treatment-naive that to questionnaires out fleet continue treat that urine that and do notion found of therapies XX,XXX not it's leads are aging people over know advanced
center to with in community. their continues qualified to local call physician work Our leads diligently a connect specialist
to Feedback requires at useful has months Axonics the the implanted we expected device as from the recharging factor small initiatives, of device of month in utilizes for hour. regulatory has body device Now customers an neurostimulator and FDA received same that recently years. overwhelmingly to just once the rechargeable form XCC approval the the XX life every have The been least turning RXX product in RXX The January. from one ten six development for positive.
to the recharge the in SNM long-lived States. a continues FXX significant sales United represent free system portion said, That of
an diary introduced week, for in App available this Android myAxonics, Stores. which Now, for and we electronic past now Apple the also is called free download
cloud-based results care diary, While, anyone it to upload we patient our that electronic portal. to patients move paper into diaries format can an to developed us from use the management electronic allows diary
neuromodulation used records these to store for customers Since and for patient's to able is pre-authorization being results is helpful our and nice are service, diary reimbursement confirm a sacral eligibility a processes. with
is scratching underserved we are underpenetrated surface we possible just closing, participate. which what large of in feel the in markets the we like in Now
team mission-driven of supporting as dedicated our our their committed Our as innovating therapies. and remains customers well best-in-class raising physician patients, awareness and to
So with turn like to I'd that on said, for to the over results. Dan remarks call detailed his colleague Dan? my financial
